109 related articles for article (PubMed ID: 1563848)
1. An organoid culture assay (OCA) for determining the drug sensitivity of human tumors.
Köpf-Maier P; Kolon B
Int J Cancer; 1992 Apr; 51(1):99-107. PubMed ID: 1563848
[TBL] [Abstract][Full Text] [Related]
2. A new approach for realizing the "antioncogram".
Köpf-Maier P
Life Sci; 1992; 50(22):1711-8. PubMed ID: 1588802
[TBL] [Abstract][Full Text] [Related]
3. Head and neck cancer organoids established by modification of the CTOS method can be used to predict in vivo drug sensitivity.
Tanaka N; Osman AA; Takahashi Y; Lindemann A; Patel AA; Zhao M; Takahashi H; Myers JN
Oral Oncol; 2018 Dec; 87():49-57. PubMed ID: 30527243
[TBL] [Abstract][Full Text] [Related]
4. Efficient use of patient-derived organoids as a preclinical model for gynecologic tumors.
Maru Y; Tanaka N; Itami M; Hippo Y
Gynecol Oncol; 2019 Jul; 154(1):189-198. PubMed ID: 31101504
[TBL] [Abstract][Full Text] [Related]
5. Organoid reorganization of human tumors under in vitro conditions.
Köpf-Maier P; Zimmermann B
Cell Tissue Res; 1991 Jun; 264(3):563-76. PubMed ID: 1868523
[TBL] [Abstract][Full Text] [Related]
6. Organoid Culture of Isolated Cells from Patient-derived Tissues with Colorectal Cancer.
Xie BY; Wu AW
Chin Med J (Engl); 2016 Oct; 129(20):2469-2475. PubMed ID: 27748340
[TBL] [Abstract][Full Text] [Related]
7. Establishment of 2.5D organoid culture model using 3D bladder cancer organoid culture.
Abugomaa A; Elbadawy M; Yamanaka M; Goto Y; Hayashi K; Mori T; Uchide T; Azakami D; Fukushima R; Yoshida T; Shibutani M; Yamashita R; Kobayashi M; Yamawaki H; Shinohara Y; Kaneda M; Usui T; Sasaki K
Sci Rep; 2020 Jun; 10(1):9393. PubMed ID: 32523078
[TBL] [Abstract][Full Text] [Related]
8. Colorimetric chemosensitivity testing using sulforhodamine B.
Kubota T; Takahara T; Nagata M; Furukawa T; Kase S; Tanino H; Ishibiki K; Kitajima M
J Surg Oncol; 1993 Feb; 52(2):83-8. PubMed ID: 8468977
[TBL] [Abstract][Full Text] [Related]
9. A comparison of clonogenic, microtetrazolium and sulforhodamine B assays for determination of cisplatin cytotoxicity in human ovarian carcinoma cell lines.
Perez RP; Godwin AK; Handel LM; Hamilton TC
Eur J Cancer; 1993; 29A(3):395-9. PubMed ID: 8398340
[TBL] [Abstract][Full Text] [Related]
10. Effect of acquired cisplatin resistance on the response of a xenografted human hypopharynx carcinoma to concurrent radiochemotherapy with cisplatin.
Jäckel M; Tausch-Treml R; Köpf-Maier P
Laryngoscope; 1994 Mar; 104(3 Pt 1):329-34. PubMed ID: 8127191
[TBL] [Abstract][Full Text] [Related]
11. The Use of Endometrial Cancer Patient-Derived Organoid Culture for Drug Sensitivity Testing Is Feasible.
Girda E; Huang EC; Leiserowitz GS; Smith LH
Int J Gynecol Cancer; 2017 Oct; 27(8):1701-1707. PubMed ID: 28683005
[TBL] [Abstract][Full Text] [Related]
12. Phenotypic heterogeneity of 2D organoid reflects clinical tumor characteristics.
Fujino S; Ito A; Ohue M; Yasui M; Mizushima T; Doki Y; Mori M; Miyoshi N
Biochem Biophys Res Commun; 2019 May; 513(2):332-339. PubMed ID: 30955861
[TBL] [Abstract][Full Text] [Related]
13. [Organoid forming method--a new in vitro chemosensitivity test].
Kikuchi H; Ujiie S; Itoh Y; Wakui A
Gan To Kagaku Ryoho; 1994 Feb; 21(3):351-62. PubMed ID: 8109991
[TBL] [Abstract][Full Text] [Related]
14. Model of Patient-Specific Immune-Enhanced Organoids for Immunotherapy Screening: Feasibility Study.
Votanopoulos KI; Forsythe S; Sivakumar H; Mazzocchi A; Aleman J; Miller L; Levine E; Triozzi P; Skardal A
Ann Surg Oncol; 2020 Jun; 27(6):1956-1967. PubMed ID: 31858299
[TBL] [Abstract][Full Text] [Related]
15. New colorimetric cytotoxicity assay for anticancer-drug screening.
Skehan P; Storeng R; Scudiero D; Monks A; McMahon J; Vistica D; Warren JT; Bokesch H; Kenney S; Boyd MR
J Natl Cancer Inst; 1990 Jul; 82(13):1107-12. PubMed ID: 2359136
[TBL] [Abstract][Full Text] [Related]
16. Testing Susceptibility of Patient-Derived Organoid Cultures to Therapies: Pharmacotyping.
Burkhart RA; Baker LA; Tiriac H
Methods Mol Biol; 2018; 1787():253-261. PubMed ID: 29736724
[TBL] [Abstract][Full Text] [Related]
17. Drug Sensitivity Assays of Human Cancer Organoid Cultures.
Francies HE; Barthorpe A; McLaren-Douglas A; Barendt WJ; Garnett MJ
Methods Mol Biol; 2019; 1576():339-351. PubMed ID: 27628132
[TBL] [Abstract][Full Text] [Related]
18. A Living Biobank of Breast Cancer Organoids Captures Disease Heterogeneity.
Sachs N; de Ligt J; Kopper O; Gogola E; Bounova G; Weeber F; Balgobind AV; Wind K; Gracanin A; Begthel H; Korving J; van Boxtel R; Duarte AA; Lelieveld D; van Hoeck A; Ernst RF; Blokzijl F; Nijman IJ; Hoogstraat M; van de Ven M; Egan DA; Zinzalla V; Moll J; Boj SF; Voest EE; Wessels L; van Diest PJ; Rottenberg S; Vries RGJ; Cuppen E; Clevers H
Cell; 2018 Jan; 172(1-2):373-386.e10. PubMed ID: 29224780
[TBL] [Abstract][Full Text] [Related]
19. Chemosensitivity testing of human tumors using a microplate adenosine triphosphate luminescence assay: clinical correlation for cisplatin resistance of ovarian carcinoma.
Andreotti PE; Cree IA; Kurbacher CM; Hartmann DM; Linder D; Harel G; Gleiberman I; Caruso PA; Ricks SH; Untch M
Cancer Res; 1995 Nov; 55(22):5276-82. PubMed ID: 7585588
[TBL] [Abstract][Full Text] [Related]
20. [Cytostatic primary therapy of squamous cell carcinoma of the oro- and hypopharynx with cisplatin, bleomycin and methotrexate].
Deitmer T; Urbanitz D
Laryngol Rhinol Otol (Stuttg); 1986 Jan; 65(1):7-10. PubMed ID: 2419720
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
